CBBB yields 990.10% · ABBV yields 3.12%● Live data
📍 CBBB pulled ahead of the other in Year 1
Combined, CBBB + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CBBB + ABBV for your $10,000?
Continental Beverage Brands Corporation provides business jet charter services to corporate and private clients. The company offers various aviation services comprising business jet charter management, such as flight scheduling, real-time flight tracking, personal travel coordination, and concierge/helpdesk services; ground transportation management, including transportation scheduling, door-to-door ground transportation coordination, reservation and booking of hotels, meeting facilities and leisure locations, as well as empty leg flights database listing and booking services. It also provides catering management services, including catering concept customization, catering suppliers coordination, aircraft stocking procedure monitoring services; aircraft decoration customization; board and ground security services; and other special services. In addition, the company offers third-party services, such as database management and administrative services for individual and fractional aircraft owners. It was formerly known as Hermes Jets, Inc. and changed its name to Continental Beverage Brands Corporation in February 2015. The company was founded in 2008 and is based in Cornelius, North Carolina. Continental Beverage Brands Corporation is a subsidiary of Raven Investments Plc.
Full CBBB Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.